Anastomotic Leak Devices Market By Product Type (Anastomosis Creation and Reinforcement Devices, Intraoperative Assessment Devices, Anastomotic Leak Treatment Devices); By Application (Colorectal Surgery, Esophageal Surgery, Gastric Surgery, Bariatric Surgery, Other Gastrointestinal Surgeries); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Surgical Centers, Therapeutic Endoscopy Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Anastomotic Leak Devices Market: Procedure Volume, Complication Costs, and Endoscopic Rescue Shape Demand

The Global Anastomotic Leak Devices Market was valued at USD 1.28 billion in 2025 and is projected to reach USD 1.99 billion by 2032, growing at a CAGR of 6.5%, according to Strategic Market Research. The forecast represents an absolute revenue increase of USD 710 million, with the market reaching approximately 1.55 times its 2025 value by 2032.

 

Devices in this market support gastrointestinal anastomosis creation, intraoperative assessment of tissue perfusion or mechanical integrity, and postoperative leak management. Key products are surgical staplers and reloads, sutures, tissue-reinforcement materials, fluorescence perfusion-imaging systems, intraoperative leak-testing devices, endoscopic clips, suturing platforms, covered stents, endoluminal vacuum systems and drainage products.

 

Demand is concentrated in colorectal resection, esophagectomy, gastrectomy, and anastomosis-forming bariatric surgery. Primary surgery produces the largest procedure base because staplers, sutures, and assessment tools can be used in every eligible operation. Rescue devices address a smaller patient group but often generate several device-use events per case through repeat endoscopy, sponge changes, clip deployment, stent exchange, or drainage.

 

Hospitals evaluate these technologies against the cost of complications rather than purchase price alone. Anastomotic leakage can cause sepsis, reoperation, intensive-care admission, prolonged nutrition support, delayed cancer treatment, readmission, and extended hospitalization. A 2025 randomized colorectal-surgery study noted that leakage can triple the financial cost of an operation. This economic burden is strengthening procurement interest in consistent stapling, intraoperative perfusion assessment, leak testing, and minimally invasive rescue pathways.

 

Colorectal Surgery Creates the Largest Commercial Base

Colorectal procedures represent the most important application because anastomoses are routinely created during operations for colorectal cancer, diverticular disease, inflammatory bowel disease, obstruction, and other bowel conditions. A meta-analysis of colon-cancer resections identified 3,959 leaks among 115,462 patients, equivalent to a pooled rate of approximately 3.4%, although incidence varies by surgical location, patient risk, and clinical definition.

Approximately 600,000 colon resection surgeries are conducted each year in the United States. On a global scale, determining the precise number of all colorectal procedures is challenging due to differences in reporting practices. However, it is estimated that millions of colorectal procedures occur annually, influenced by over 1.9 million new colorectal cancer diagnoses and numerous benign cases worldwide.

The United States recorded 305,900 inpatient stays involving colorectal resection in 2012, according to the Agency for Healthcare Research and Quality. Applying the pooled 3.4% leak rate to this procedure proxy produces approximately 10,401 potential leak events. The calculation demonstrates the scale of the treatment opportunity even before gastric, esophageal, bariatric, and other bowel procedures are included.

The underlying cancer population continues to support surgical demand. The United States is expected to record 158,850 new colorectal cancer cases and 55,230 deaths in 2026, while global colorectal cancer incidence exceeds two million cases annually. Not every patient undergoes resection, but colorectal cancer remains the largest disease pool associated with bowel anastomosis formation.

 

Esophagectomy Supports High-Intensity Rescue Demand

Esophageal surgery contributes fewer procedures than colorectal surgery but creates substantial device demand when a leak occurs. A 2025 Society of Thoracic Surgeons database analysis identified 3,416 leaks among 18,419 esophagectomies with gastric reconstruction, representing a 19% registry rate. Patients with leaks recorded 30-day mortality of 7% compared with 4% among patients without leakage, reoperation rates of 58% versus 10%, and median hospital stays of 18 versus 10 days.

A separate U.S. database study identified 29,116 esophagectomies from 2016 through 2020, averaging approximately 5,823 procedures per year. The annual procedure pool is relatively narrow, but a single complicated case may require covered stents, endoscopic clips, vacuum therapy, drainage, repeated endoscopy, or operative revision.

This creates a different revenue model from primary colorectal stapling. Colorectal devices compete on high procedure throughput, standardization, and hospital contracts. Upper gastrointestinal rescue products compete on defect closure, continuous drainage, repeat-procedure efficiency, and the ability to avoid major reoperation in selected patients.

 

Bariatric Surgery Adds a Stable Anastomosis-Formation Opportunity

Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch, and one-anastomosis gastric bypass expand demand for staplers, sutures, intraoperative assessment, and endoscopic rescue systems. The American Society for Metabolic and Bariatric Surgery estimated 63,132 Roux-en-Y gastric bypass procedures and 3,775 BPD-DS procedures in the United States in 2023. Together, these categories produced 66,907 anastomosis-forming operations and represented approximately 24.8% of the 270,089 bariatric procedures performed during the year. RYGB alone accounted for about 23.4% of U.S. bariatric procedure volume, while BPD-DS represented approximately 1.4%.

Bariatric demand is influenced by procedure mix as well as total surgical volume. Sleeve gastrectomy accounted for 157,254 U.S. procedures in 2023, or approximately 58.2% of the national bariatric procedure total, but it creates a staple line rather than a gastrointestinal anastomosis. Some closure, stenting, and vacuum products are used for sleeve leaks, creating adjacent demand without expanding the core anastomotic procedure base.

The bariatric segment is also exposed to reimbursement policy, patient preferences, long-term outcome data, and the increasing use of weight-loss medicines. Stapler and closure suppliers therefore depend on the balance between bypass procedures and sleeve gastrectomy rather than obesity prevalence alone.

 

Perfusion Imaging Moves Toward Risk-Selected Adoption

Near-infrared fluorescence imaging with indocyanine green is being integrated into colorectal and upper gastrointestinal surgery to assess blood flow before the anastomosis is completed. Commercial demand includes imaging platforms, compatible laparoscopic or robotic systems, and procedure-related consumables. Stryker’s SPY-PHI and Intuitive Surgical’s Firefly platform represent established commercial approaches.

Clinical evidence supports selective adoption rather than automatic use across every bowel operation. In the 2025 ICG-COLORAL randomized trial involving 1,136 patients, the overall leak rate was 5.8% with fluorescence imaging and 7.9% with conventional assessment. The left-sided subgroup recorded rates of 5.2% and 9.5%, respectively, while right-sided procedures showed little difference.

The EssentiAL randomized trial involving 850 rectal-cancer patients reported clinically relevant grade B or C leakage in 4.7% of the fluorescence group and 8.2% of the control group. Reoperation rates were 0.5% and 2.4%, respectively. Updated evidence has similarly indicated stronger benefit in left-colon and rectal procedures than in right-colon surgery.

Hospitals are therefore more likely to prioritize fluorescence capability for low rectal operations, left-sided resections, complex reoperations, and patients with uncertain tissue perfusion. Suppliers that improve signal interpretation, documentation, and integration with robotic or laparoscopic platforms can strengthen their position beyond basic image visualization.

 

Stapler Competition Shifts Toward Powered and Data-Assisted Firing

Surgical staplers and reloads form the largest product segment because they are used during primary operations rather than only after a complication occurs. Johnson & Johnson’s ECHELON Circular Powered Stapler and Medtronic’s EEA and Signia circular platforms compete across colorectal, gastric, bariatric, and thoracic procedures.

Medtronic announced the limited launch of its Signia Circular Stapler in late 2025, with broader availability anticipated in 2026. The platform combines powered clamping, adaptive compression, integrated leak testing, and a reusable handle. The company reported that more than 6,000 staplers are used in U.S. operating rooms each day across the broader surgical stapling category.

Clinical comparisons between powered and manual circular staplers remain mixed. Some studies and meta-analyses have reported lower leakage or bleeding with powered systems, while others found no significant difference in postoperative complications. Hospitals are therefore considering product reliability, surgeon familiarity, training, service support, and post-market evidence alongside powered firing.

Regulatory scrutiny is also shaping competition. The U.S. FDA reclassified internal surgical staplers from Class I to Class II with special controls in 2021 after reviewing more than 41,000 adverse-event reports, including 366 deaths, over 9,000 serious injuries, and more than 32,000 malfunctions associated with surgical staplers and staples between January 2011 and March 2018. Reported problems included incomplete staple lines, malformed staples, misfiring, and failure to fire.

In May 2026, the FDA classified the recall of certain Intuitive Surgical SureForm 30 gray reloads as Class I after reports of incomplete staple lines on blood vessels, including four serious injuries and one death. Although the recall concerned vascular use, it reinforces the commercial importance of manufacturing consistency, traceability, supply continuity, and post-market surveillance across robotic and conventional stapling platforms.

 

Endoscopic Rescue Devices Generate Repeat Procedure Revenue

Leak-treatment devices address fewer patients than primary surgical products, but treatment intensity can be substantially higher. The segment includes over-the-scope clips, endoscopic suturing platforms, covered stents, endoluminal vacuum sponges, drains, guidewires, and retrieval accessories. Product selection depends on defect size, location, tissue condition, contamination, patient stability, and local expertise.

A 2025 meta-analysis of six observational studies involving 273 patients found that endoscopic vacuum therapy was associated with higher leak-resolution rates and shorter treatment duration than standard care for colorectal anastomotic leakage. This evidence is supporting broader interest in structured vacuum-therapy pathways at specialist centres.

Boston Scientific markets Endo-SPONGE for low-pelvic colorectal leaks and Eso-SPONGE for upper gastrointestinal defects in Europe. Its European materials cite a 91% closure rate from a prospective study involving 281 colorectal patients. Ovesco’s OTSC platform competes in smaller defects and selected leaks where tissue can be securely captured. A pooled analysis of 107 treated colorectal leak or fistula patients reported technical success of 84% and clinical success of 74.3%.

Boston Scientific’s OverStitch platform extends endoscopic closure into larger or irregular defects that may not be suitable for clips alone. Combined technologies such as VACStent pair luminal coverage with negative-pressure treatment and are gaining attention in Europe. Adoption will depend on regulatory availability, specialist training, repeat-procedure requirements, and evidence comparing these products with conventional stents, vacuum sponges, and surgery.

 

Product and End-User Segmentation

Anastomosis-creation and reinforcement devices generate the largest recurring revenue because staplers, reloads, sutures, and reinforcement materials are used during primary surgery. Colorectal procedures form the dominant application, followed by bariatric, gastric, and esophageal reconstruction.

Within the broader USD 15.4 billion colorectal surgery market, stapling devices accounted for approximately 29% of 2024 revenue, equivalent to about USD 4.47 billion. Sutures held approximately 21%, representing nearly USD 3.23 billion. These figures cover the wider colorectal surgery ecosystem, but their revenue weight reflects the central role of stapling and suturing in bowel resection, reconstruction, anastomosis formation, and leak prevention.

Intraoperative assessment devices include fluorescence-imaging systems, compatible camera platforms, consumables, and mechanical or air-leak testing products. Capital equipment creates larger initial contract values, while consumables provide recurring procedure revenue. Hospitals obtain greater value when the same imaging platform can support gastrointestinal, hepatobiliary, reconstructive, and robotic procedures.

Robotic systems contributed approximately 18% of the broader colorectal surgery market in 2024, equivalent to about USD 2.77 billion, and are expected to remain its fastest-growing product category through 2030. Although robotic platform revenue extends beyond leak prevention, the expansion of fluorescence-enabled and digitally assisted surgery increases the installed base for perfusion assessment and robotic stapling.

Leak-treatment devices include clips, suturing systems, covered stents, vacuum therapy, and drainage products. This segment serves a smaller patient population but can generate several device-use events during one treatment episode.

Hospitals remain the dominant end users because major gastrointestinal surgery and unstable postoperative complications require inpatient surgical, endoscopic, radiological, nutritional, and intensive-care support. Tertiary hospitals with advanced endoscopy and high colorectal or upper gastrointestinal volumes represent the most commercially attractive accounts.

 

Regional Market Dynamics

North America represents a high-value market because of its colorectal and bariatric procedure base, installed robotic-surgery infrastructure, use of powered stapling, and access to fluorescence imaging and advanced endoscopic closure. Within the broader surgical ecosystem, the U.S. colorectal surgery market was valued at USD 4.77 billion in 2024 and is projected to reach USD 6.92 billion by 2030, growing at a CAGR of 6.3%. Strict post-market surveillance also makes safety history, supply reliability, and training important purchasing criteria.

Europe has a strong position in endoluminal vacuum therapy. Boston Scientific’s Endo-SPONGE and Eso-SPONGE, Ovesco’s closure systems, and emerging VACStent technologies support wider use of structured endoscopic leak-management pathways. The wider European colorectal surgery market is projected to increase from USD 4.00 billion in 2024 to USD 5.43 billion by 2030 at a CAGR of 5.2%, providing a substantial procedure-linked base for stapling, assessment, and rescue technologies.

Asia-Pacific offers substantial long-term opportunity because the region carries a large share of global colorectal and gastric cancer cases and includes major surgical-device markets such as Japan, China, South Korea, Australia, and India. The region’s broader colorectal surgery market is projected to rise from USD 3.08 billion in 2024 to USD 4.80 billion by 2030, registering a CAGR of 7.6%—faster than the corresponding U.S. and European markets. Adoption remains uneven, with leading urban hospitals using robotic surgery, fluorescence imaging, powered stapling, and advanced endoscopy while capital and specialist limitations restrict access in lower-resource settings.

 

Competitive Landscape and Market Outlook

Johnson & Johnson and Medtronic compete most directly in circular and linear stapling. Stryker and Intuitive participate through fluorescence-capable imaging and robotic platforms. Boston Scientific combines endoscopic suturing, stenting, and region-specific vacuum therapy, while Ovesco holds a specialist position in over-the-scope closure. VACStent and Möller Medical represent the emerging combined stent-vacuum category.

Competition is expanding beyond the stapler itself. Stapler companies are adding powered firing, compression feedback, testing functions, and reusable components. Imaging companies are embedding fluorescence into broader surgical platforms. Endoscopy suppliers are combining closure, drainage, suturing, and defect-isolation products.

Staplers, reloads, and primary surgical products will remain the largest revenue pool through 2032. Fluorescence imaging is expected to expand most strongly in left-sided and rectal procedures where clinical evidence is more supportive. Endoscopic vacuum therapy, clips, suturing, and covered stents will gain importance as tertiary hospitals formalize rescue pathways intended to avoid reoperation in suitable patients.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.28 Billion
Revenue Forecast in 2032	USD 1.99 Billion
Overall Growth Rate	CAGR of 6.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Anastomosis Creation and Reinforcement Devices [Surgical Staplers and Reloads, Surgical Sutures, Tissue Reinforcement Products]; Intraoperative Assessment Devices [Fluorescence Perfusion Imaging Systems, Mechanical and Air-Leak Testing Devices]; Anastomotic Leak Treatment Devices [Endoscopic Clips, Endoscopic Suturing Systems, Covered Stents, Endoluminal Vacuum Therapy Systems, Surgical and Percutaneous Drainage Devices]
By Application	Colorectal Surgery, Esophageal Surgery, Gastric Surgery, Bariatric Surgery, Other Gastrointestinal Surgeries
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Surgical Centers, Therapeutic Endoscopy Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising volume of colorectal, gastric, esophageal, and bariatric procedures; increasing clinical focus on preventing postoperative complications and hospital readmissions; wider adoption of fluorescence-based perfusion assessment and intraoperative leak testing; growing use of minimally invasive endoscopic systems for leak closure, drainage, and vacuum-assisted treatment
Customization Option	Available upon request